Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 4Phase 1 4Phase EARLY_PHASE1 1

Status

Recruiting 3Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Melanoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × defactinib × Clear all
NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
182 enrolled
CNS

Glioblastoma

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting
33 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT03287271 2024-08-12

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California, San Diego

Phase 1/2 Recruiting
90 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

NHS Greater Glasgow and Clyde

Phase 1/2 Unknown
59 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡